Zuventus has always been at the forefront in bringing innovation and excellence in Healthcare.

As part of this commitment to the medical fraternity & patients, Zuventus introduced a novel concept-based molecule, Trelagliptin (Trelaglip), a Once-Weekly Oral DPP4i for the management of Type 2 Diabetes Mellitus (T2DM), designed to address existing challenges in glycemic control & patient compliance.

Trelaglip makes a difference to QoL with Compliance & Control, available in 3 SKUs (100 MG, 50 MG & 25 MG) 

• For the first time in India, Zuventus conducted a clinical trial comparing Trelagliptin 100 MG (once-weekly) vs. Vildagliptin 50 MG BID & got CDSCO approval.

Know More about Trelaglip